Results 1 to 10 of about 19,211 (198)

Functional characterization of the defective CYP2C9 variant CYP2C9*18 [PDF]

Pharmacology Research & Perspectives, 2021
Cytochrome P450 2C9 (CYP2C9) is one of the most important drugs metabolizing enzymes and accounts for the metabolism of about 13%–17% of clinical drugs.
Jian Liu, Hao Chen, Shuang‐Hu Wang, Quan Zhou, Pei‐Wu Geng, Yun‐Fang Zhou, Hua‐Lan Wu, Hai‐Feng Shi, Fang Wang, Jie‐Fu Yang, Jian‐Ping Cai, Da‐Peng Dai   +11 more
doaj   +3 more sources

Efavirenz and CYP2C9 Genetic Polymorphisms Reduce CYP2C9 Activity in Healthy Participants. [PDF]

Clin Transl Sci
ABSTRACT Efavirenz's effects on cytochrome P450 2C9 (CYP2C9) activity have not been formally characterized in vivo. We conducted the first clinical drug–drug interaction (DDI) study to test the effect of chronic efavirenz dosing on CYP2C9 activity, using tolbutamide as a selective probe.
Kim JD, Metzger IF, Lu JBL, Skaar TC, Desta Z.   +4 more
europepmc   +3 more sources

Human CYP2C9 Metabolism of Organophosphorus Pesticides and Nerve Agent Surrogates [PDF]

Journal of Xenobiotics
Of the Cytochrome P450 enzymes, the CYP2C9 variant is very important in the metabolism of several human drugs, acting as a natural bioscavenger. Previously, CYP2C9 was shown to convert the thion (P=S) to the oxon (P=O) form for some organophosphorus (OP)
Pratik Shriwas, Abigail M. Noonchester, Andre Revnew, Thomas R. Lane, Christopher M. Hadad, Sean Ekins, Craig A. McElroy   +6 more
doaj   +2 more sources

Evaluation of CYP2C8 and CYP2C9 Polymorphisms in Neonates with Patent Ductus Arteriosus Treated with Ibuprofen or Indomethacin: A Retrospective Cohort Study [PDF]

Journal of Cardiovascular Development and Disease
The pharmacologic management of patent ductus arteriosus (PDA) presents a challenge to clinicians due to the interindividual variability in drug response to available medications.
Shaikha Jabor Alnaimi, Shimaa Aboelbaha, Ibrahim Safra, Mai Abdulla Al Qubaisi, Fouad Abounahia, Ahmed Al Farsi, Liji Cherian, Lizy Philip, Moza Alhail, Gulab Sher, Nader Al-Dewik   +10 more
doaj   +2 more sources

PharmVar GeneFocus: CYP2C9 [PDF]

Clinical Pharmacology & Therapeutics, 2021
The Pharmacogene Variation Consortium (PharmVar) catalogues star (*) allele nomenclature for the polymorphic human CYP2C9 gene. Genetic variation within the CYP2C9 gene locus impacts the metabolism or bioactivation of many clinically important drugs, including nonsteroidal anti‐inflammatory drugs, phenytoin, antidiabetic agents, and angiotensin ...
Sangkuhl, Katrin, Claudio‐Campos, Karla, Cavallari, Larisa H., Agundez, Jose A.G., Whirl‐Carrillo, Michelle, Duconge, Jorge, Del Tredici, Andria L., Wadelius, Mia, Rodrigues Botton, Mariana, Woodahl, Erica L., Scott, Stuart A., Klein, Teri E., Pratt, Victoria M., Daly, Ann K., Gaedigk, Andrea   +14 more
openaire   +3 more sources

Impact of genetic and non-genetic factors on hepatic CYP2C9 expression and activity in Hungarian subjects

Scientific Reports, 2021
CYP2C9, one of the most abundant hepatic cytochrome P450 enzymes, is involved in metabolism of 15–20% of clinically important drugs (warfarin, sulfonylureas, phenytoin, non-steroid anti-inflammatory drugs).
Ferenc Fekete, Katalin Mangó, Máté Déri, Evelyn Incze, Annamária Minus, Katalin Monostory   +5 more
doaj   +1 more source

Clinical significance of the series of CYP2C9*non3 variants, an unignorable predictor of warfarin sensitivity in Chinese population

Frontiers in Cardiovascular Medicine, 2022
BackgroundsGene polymorphisms are critical for variations in warfarin dose. To date, more than 70 CYP2C9 alleles have been identified. This study was designed to clarify the clinical significance of CYP2C9*non-3 variants to warfarin sensitivity in ...
Dongxu Wang, Dongxu Wang, Hualan Wu, Min Dong, Qing Zhang, Anxu Zhao, Xinlong Zhao, Jia Chong, Minghui Du, Yan Wang, Haifeng Shi, Shuanghu Wang, Fang Wang, Jianping Cai, Jiefu Yang, Dapeng Dai, Hao Chen   +16 more
doaj   +1 more source

Association between CYP2C9 and CYP2C19 Polymorphism, Metabolism, and Neurotoxicity after Administration of Phenytoin: A Systematic Review

Keluwih, 2023
—Phenytoin is an antiepileptic drug (AED) metabolized by cytochrome P450 enzymes, especially by CYP2C9 (90%) and CYP2C19 (10%), where both enzymes are polymorphic so that they can undergo polymorphism and it can change the metabolic rate of the drug ...
Rizka Mardhiani, Yahdiana Harahap, Winnugroho Wiratman   +2 more
doaj   +1 more source

Genetic abnormality of cytochrome-P2C9*3 allele predisposes to epilepsy and phenytoin-induced adverse drug reactions: genotyping findings of cytochrome-alleles in the North Indian population

Future Journal of Pharmaceutical Sciences, 2022
Background This research aims to study the association of genetic polymorphism in genes coding for CYP2C9 and CYP2C19 in phenytoin-induced dose-related toxicity and to assess if the presence of allele CYP2C9*3 plays a role in phenytoin-induced ...
Vivek Kumar Garg, Supriya, Ritu Shree, Ajay Prakash, Aastha Takkar, Madhu Khullar, Biman Saikia, Bikash Medhi, Manish Modi   +8 more
doaj   +1 more source

Pharmacogenetics of sulfonylurea: Presence of CYP2C9*2, CYP2C9*3 and a novel allele, CYP2C9*61, in Type 2 diabetes patients under sulfonylurea therapy

Pakistan Journal of Pharmaceutical Sciences, 2020
CYP2C9 is an important member of the cytochrome P450 gene family involved in the metabolism of 15% of the drugs including an oral antidiabetic agent sulfonylurea.
Sumaira Deen Muhammad, Hazar Khan, Mushtaq Hussain, Tehseen Fatima Zeb, Darshan Kumar, Rahimullah Rahi, Mahayrookh Asif, Akhter Ali Balooch   +7 more
doaj   +1 more source